0
No votes yet
Article

The Changing Landscape of Multiple Myeloma

Sandra Kurtin
Beth Faiman
CJON 2013, 17(6), 7-11 DOI: 10.1188/13.CJON.S2.7-11

Scientific advancements relative to diagnostic evaluation, risk-adapted treatment selection, and supportive care strategies for multiple myeloma (MM) have been developed in the past decade, which provides hope for patients living with MM. However, the disease remains incurable for the majority of patients, and continued clinical trials are necessary to refine existing therapeutic strategies and develop new approaches to treatment. Hematopoietic stem cell transplantation (HSCT), in particular autologous HSCT, remains an important component in the overall treatment paradigm for MM. This requires a well-organized team approach with ongoing communications and collaboration with community providers and other specialists. The majority of care for patients with MM is provided in the outpatient setting, relying on the active participation of both the patient and caregiver(s) for successful clinical outcomes. This supplement is prepared by members of the International Myeloma Foundation Nurse Leadership Board, which is dedicated to improving the care of patients with MM and their caregivers. The introduction serves to provide an overview of MM today and to summarize the articles included in this supplement.

References 

Agarwal, A., & Ghobrial, I. M. (2012). Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: A review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. <i>Clinical Cancer Research, 19</i>, 985-994. doi:10.1158/1078-0432.CCR-12-2922

American Cancer Society. (2013). Cancer facts and figures 2013. Retrieved from <a target="_blank" href='http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/can...

Durie, B. G., Kyle, R. A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., … Van Ness, B. (2003). Myeloma management guidelines: A consensus report from Scientific Advisors of the International Myeloma Foundation. <i>Hematology Journal, 4</i>, 379-398. doi:10.1038/sj.thj.6200312

Faiman, B., Miceli, T., Noonan, K., & Lilleby, K. (2013). Clinical update in bone marrow transplantation in multiple myeloma. <i>Clinical Journal of Oncology Nursing, 17</i>(Suppl., 2), 33-41. doi:10.1188/13.CJON.S2.33-41

Kuehl, W. M., & Bergsagel, P. L. (2002). Multiple myeloma: Evolving genetic events and host interactions. <i>Nature Reviews: Cancer, 2</i>, 175-187. doi:10.1038/nrc746

Kumar, S., Dispenzieri, A., Gertz, M., Lacy, M., Lust, J., Hayman, S., … Rajkumar, S. V. (2012). <i>Continued improvement in survival in multiple myeloma and the impact of novel agents</i> [Abstract 3972]. Retrieved from <a target="_blank" href='http://myeloma.org/pdfs/ASH2012_Kumar_3865.pdf'>http://myeloma.org/pdfs/...

Kurtin, S., Lilleby, K., & Spong, J. (2013). Caregivers of multiple myeloma survivors. <i>Clinical Journal of Oncology Nursing, 17</i>(Suppl., 2), 25-32. doi:10.1188/13.CJON.S2.25-32

Mangan, P., Gleason, C., & Miceli, T. (2013). Autologous hematopoietic stem cell transplantation for multiple myeloma: Frequently asked questions. <i>Clinical Journal of Oncology Nursing, 17</i>(Suppl., 2), 43-47. doi:10.1188/13.CJON.S2.43-47

Miceli, T., Lilleby, K., Noonan, K., Kurtin, S., Faiman, B., & Mangan, P. (2013). Autologous hematopoietic stem cell transplantation for patients with multiple myeloma. An overview for nurses in community practice. <i>Clinical Journal of Oncology Nursing, 17</i>(Suppl., 2), 13-24. doi:10.1188/13.CJON.S2.13-24

National Cancer Institute. (2010). SEER stat fact sheets: Myeloma. Retrieved from <a target="_blank" href='http://seer.cancer.gov/statfacts/html/mulmy.html'>http://seer.cancer.gov...

National Comprehensive Cancer Network. (2013). NCCN Clinical Practice Guidelines in Oncology: Multiple myeloma [v.1.2013]. Retrieved from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#myeloma...

Palumbo, A., & Anderson, K. (2011). Multiple myeloma. <i>New England Journal of Medicine, 364</i>, 1046-1060. doi:10.1056/NEJMra1011442

Palumbo, A., & Cavallo, F. (2012). Have drug combinations supplanted stem cell transplantation in myeloma? <i>Blood, 120</i>, 4692-4698. doi:10.1182/blood-2012-05-423202

Perotta, C., Kleefeld, S., Staines, A., Tewari, P., De Roos, A. J., Baris, D., … Cocco, P. (2013). Multiple myeloma and occupation: A polled analysis by the International Multiple Myeloma Consortium. <i>Cancer Epidemiology, 37</i>, 300-305. doi:10.1016/j.canep.2013.01.008

Rajkumar, S. V. (2010). Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology, 86</i>, 57-65. doi:10.1002/ajh.21913

Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J., Bradwell, A. R., Clark, R. J., … Katzmann, J. A. (2005). Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. <i>Blood, 106</i>, 812-817. doi:10.1182/blood-2005-03-1038

Siegel, D. S., & Bilotti, E. (2009). New directions in therapy for multiple myeloma. <i>Community Oncology, 6</i>(Suppl., 3), 22-30.

Vacca, A., & Ribatti, D. (2006). Bone marrow angiogenesis in multiple myeloma. <i>Leukemia, 20</i>, 193-199. doi:10.1182/blood-2005-03-1038

Wallin, A., & Larson, S. C. (2011). Body mass index and risk of multiple myeloma: A meta-analysis of prospective studies. <i>European Journal of Cancer, 47</i>, 1606-1611. doi:10.1016/j.ejca.2011.01.020